PsyLabs develops and produces certified pharmaceutical-grade nature-derived psychedelics for applications in mental health and well-being Psyence Biomedical has issued common shares to Psyence Group pursuant to a debt-for-equity swap agreement NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc. ("Psyence Group") (CSE: PSYG) today announced the successful closing of its previously announced disposal of its 11.13%... Read More

Empax Center brings significant expertise in clinical trial execution for mental health and neurological conditions Psyence Biomed on track to begin recruitment this quarter, and to announce Adjustment Disorder topline data in the second half of 2025 NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc (" Psyence Group ") (CSE: PSYG), a life science biotechnology company pioneering the use of nature-derived... Read More

TORONTO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) hereby announces that it has entered into a debt-for-equity swap agreement (the " Debt Swap Agreement ") with its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) (" PBM " or " Psyence Biomed "), pursuant to which Psyence Biomed has agreed to issue to the Company 2,075,920 Psyence Biomed common shares at a... Read More

NEW YORK, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc (" Psyence Group " or the " Company ") (CSE: PSYG) (as seller), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, today announced that it has entered into a conditional share sale agreement with its NASDAQ-listed associate, Psyence Biomedical Ltd. (Nasdaq: PBM) (" Psyence Biomed " or " PBM ") (as... Read More

Initiated Phase IIb study of nature-derived psilocybin as a potential treatment for Adjustment Disorder in Palliative Care Expanded pipeline into Alcohol Use Disorder (AUD) and Substance Use Disorders (SUDs) through exclusive IP licensing agreement with Psylabs for its botanical psilocybin product Announced potential acquisition of synthetic psilocybin-based drug developer Clairvoyant Therapeutics, further bolstering AUD... Read More

NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc (" Psyence Group ") (CSE: PSYG), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, is pleased to announce that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) (" PBM " or " Psyence Biomed "), has successfully completed the first site initiation visit at the first Australian... Read More

NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc (" Psyence Group ") (CSE: PSYG), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, is pleased to announce that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) (" PBM " or " Psyence Biomed "), has announced the export of nature-derived psilocybin to Australia and provided an update... Read More

NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc (" Psyence Group ") (CSE: PSYG), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, is pleased to announce that its NASDAQ listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) (" PBM " or " Psyence Biomed "), has announced that its Australian subsidiary, Psyence Australia Pty Ltd (" Psyence... Read More

TORONTO, March 26, 2024 (GLOBE NEWSWIRE) -- Further to the announcement by Psyence Group Inc (" Psyence " or the " Company ") (CSE:PSYG) of its plans for the strategic restructuring of its non-clinical business through a conditional M&A transaction (the " Transaction "), Psyence is pleased to announce that the conditions to implement the Transaction have been met and that the Transaction has closed. Psyence has built a... Read More

NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc (" Psyence Group ") (CSE: PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, is pleased to announce that its NASDAQ listed associate, Psyence Biomedical Ltd (NASDAQ:PBM) (" PBM " or " Psyence Biomed ") has received full approval from the Australian Health Research Ethics... Read More

TORONTO, March 11, 2024 (GLOBE NEWSWIRE) -- Further to the announcement by Psyence Group Inc (" Psyence Group " or the " Company ") (CSE:PSYG) of the closing (the "Closing") of the business combination of its subsidiary, Psyence Biomedical Ltd (" PBM ") ( NASDAQ : PBM ) with Newcourt Acquisition Corp (" Newcourt "), a special purpose acquisition company, (the " Business Combination " or " Spin - Out ") and the subsequent... Read More

TORONTO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (“Psyence Biomed”) is excited to announce the completion of its merger (the “Business Combination”) with Newcourt Acquisition Corp ("Newcourt"), a special purpose acquisition company. The Business Combination will list Psyence Biomed, a subsidiary of Psyence Group Inc (CSE:PSYG), a clinical-stage life science biotechnology company pioneering the use of... Read More

TORONTO, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group") (CSE:PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, today announced that its subsidiary, Psyence Biomedical Ltd ("Pubco"), has entered into a definitive securities purchase agreement (the "Securities Purchase Agreement") providing for up to US$10 million in... Read More

TORONTO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE:PSYG) (“ Psyence ” or the “ Company ”), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing announced today that Mr. Marvin Singer has resigned from his position as a Non-Executive Director for personal reasons. Mr. Singer has been an integral part of the board of the Company since... Read More

TORONTO, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE:PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing (“Psyence”), and Newcourt Acquisition Corp (Nasdaq: NCAC) (“Newcourt”), a special purpose acquisition company today announced that the registration statement on Form F-4 (the “Registration Statement”), filed by Psyence... Read More

TORONTO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc . (CSE:PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing (“ Psyence ”), is pleased to provide the following update on Psyence Production . Psyence Production is a division of Psyence that oversees its psilocybin cultivation and production facility. Psyence operates one of the... Read More

TORONTO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE:PSYG | OTCQB:PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, announces that it has issued 1,056,441 common shares at a price of CAD$0.12 per common share for gross proceeds of CAD$126,773. In connection with this issuance, the Company also issued 17,691... Read More

VANCOUVER, British Columbia, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE:PSYG | OTCQB: PSYGF), a clinical-stage life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being (“ Psyence ”), and Newcourt Acquisition Corp (“ Newcourt ”) (Nasdaq: NCAC), a special purpose acquisition company (“ SPAC ”) today announced the entry into an amended and restated business... Read More

Highlights: Drug development, Phase IIb clinical trial advanced planning underway in Australia Psyence granted worldwide licensing agreement to commercialize Filament’s PEX010 (25 mg) in palliative care with exclusivity in key markets Successful completion of exports of medical grade psilocybin mushrooms to three key global markets Extraction capabilities enhanced at Psyence’s production facility Christopher Bull appointed... Read More

TORONTO, July 11, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”) is pleased to announce the appointment of Christopher Bull to the board of directors of the Company effective immediately. Mr. Bull is a qualified chemical engineer, attorney, patent attorney and Certified Licensing Professional®. Over his 30-year career Mr. Bull has been an investor, director, founder, and... Read More

TORONTO, April 03, 2023 (GLOBE NEWSWIRE) -- Psyence Group inc. (CSE:PSYG | OTCQB:PSYGF) ("Psyence" or the "Company"), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that it has issued 9,043,038 common shares at a price of CAD$0.12 per common share for gross proceeds of CAD$1,085,164. This brings the total amount the Company has raised... Read More

VANCOUVER, British Columbia, March 23, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc (CSE:PSYG | OTCQB: PSYGF), a life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being, is pleased to announce that it has entered into a brokered subscription agreement with Cantheon Capital, LLC ("Cantheon"). Cantheon, a fund focussed on listed biotech stocks with near term catalysts, will... Read More

VANCOUVER, British Columbia, March 21, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc (CSE:PSYG | OTCQB: PSYGF), a life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being, is pleased to announce that its newly incorporated wholly owned Australian subsidiary, Psyence Australia Pty Ltd, has partnered with iNGENū Pty Ltd (iNGENū) to conduct Psyence’s previously announced clinical... Read More

TORONTO, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG. |. OTCQB: PSYGF) (Psyence or the Company), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that it has entered into a partnership with Eden Labs LLC, (“ Eden Labs ”) a product development and extraction technology company that has developed intellectual property and... Read More

TORONTO, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”) is pleased to announce that it has exported purified pharmaceutical grade psilocybin mushroom extract to its Contract Development & Manufacturing Organisation (“CDMO”) partner in the United Kingdom. The product was exported from Psyence’s federally licensed ISO22000 certified production facility in Southern... Read More

VANCOUVER, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE:PSYG | OTCQB: PSYGF), a life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being (“Psyence”), and Newcourt Acquisition Corp (Nasdaq: NCAC), a special purpose acquisition company (“SPAC”) formed for the purpose of acquiring or merging with one or more businesses (“Newcourt” or the... Read More

VANCOUVER, British Columbia, Jan. 08, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc ( CSE:PSYG | OTCQB: PSYGF), a life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being, today announced that it has signed a Letter of Intent (LOI) with Contract Research Organisation (CRO) iNGENū CRO Pty Ltd (iNGENū) to execute Psyence’s strategy of market leading clinical development of... Read More

VANCOUVER, British Columbia, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) (“Filament”), a clinical-stage natural psychedelic drug development company, and Psyence Group Inc (CSE:PSYG | OTCQB: PSYGF) (“Psyence” and, together with Filament, the “Companies”), a life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being, today announced... Read More

TORONTO, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being is pleased to announce that it has closed the second tranche of its previously announced private placement of up to CAD$3 million. The Company has issued 7,751,859 common shares at a price of... Read More

TORONTO, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that it has, together with its joint venture partner The Goodleaf Company (Pty) Ltd (“Goodleaf”), entered into an exclusive distribution agreement with This Works Products... Read More

TORONTO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“ Psyence ” or the “ Company ”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that it has received subscription agreements for gross proceeds of CAD$1.22 million from a consortium led by Brandon Kerzner, a member of the globally recognised Kerzner... Read More

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“ Psyence ” or the “ Company ”) is pleased to announce that it has successfully exported medical grade psilocybin mushrooms to Psilo Pharma Inc. (“Psilo Pharma”), from its federally licensed ISO22000 certified production facility in Southern Africa, through its research partner in Portugal (the “Research Partner”). In February 2022, Psyence received an import permit from the... Read More

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“ Psyence ” or the “ Company ”) has successfully exported psilocybin mushrooms to Psilo Scientific Ltd. in Canada. Psilo Scientific, a wholly owned subsidiary of Filament Health Corp., is an exclusively natural psychedelic drug discovery and extraction company. Psyence received a Health Canada import permit obtained by Psilo Scientific in March 2022. The psilocybin mushrooms... Read More

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (" Psyence " or the " Company "), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is delighted to announce that it has received approval for its Phase IIa clinical trial from the Medicines and Healthcare products Regulatory Agency (MHRA), the UK equivalent regulatory body to Canada’s Health Canada and the US’s FDA.... Read More

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (" Psyence " or the " Company "), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce, further to the Company’s press release dated December 2, 2021, the amendment and closing of its first tranche of the previously announced non-brokered private placement offering (the " Private Placement ")... Read More

Partnership with CRO Clerkenwell Health to design and deliver Psyence’s UK clinical trial progressing; exclusive licensing agreement with Filament Health Dr. Clive Ward-Able has been appointed as Medical Director, Head of Research & Development and Early Commercialization for Psyence ISO22000 certified commercial psilocybin production facility and lab upgraded Received an import permit from Health Canada on behalf of Psilo... Read More

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“ Psyence ” or the “ Company ”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce the appointment of Dr. Clive Ward-Able as the Medical Director of Psyence Group, effective immediately. Dr. Ward-Able joins the existing medical team in Toronto and also assumes the roles of Head of Research &... Read More

Psyence Group Inc (CSE: PSYG | OTCQB: PSYGF) (“Psyence”), a life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being, and Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) (“Filament”), a clinical-stage natural psychedelic drug development company, today announced the conclusion of an exclusive licensing agreement. Under the terms of the agreement, Filament will license... Read More

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“ Psyence ” or the “ Company ”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that the Company’s common shares are now eligible for electronic clearing and settlement through the Depository Trust Company (“DTC”) in the United States (“US”). DTC is a subsidiary of the Depository Trust &... Read More

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“ Psyence ” or the “ Company ”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that its ISO22000 graded Psilocybin production facility has officially received International Organization for Standardization ( ISO ) 22000:2018 certification, awarded through the British Standards Institute (... Read More

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“ Psyence ” or the “ Company ”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, announces that it is exploring capital market opportunities to access a broader pool of United Kingdom (“UK”) and European investors. This includes a potential dual listing in the UK. This forms part of the Company’s strategy to... Read More

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“ Psyence ” or the “ Company ”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that Psyence Chief Executive Officer, Neil Maresky , will be presenting at the virtual H.C. Wainwright 2 nd Annual Psychedelics Conference on December 6 th , 2021. For more information about the event and to... Read More

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“ Psyence ” or the “ Company ”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, announces that it is commencing a non-brokered private placement offering of up to CAD$2,000,000 of unsecured convertible promissory notes (the “ Notes ”). The Notes are convertible at the option of the holder at any time and will be... Read More

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“ Psyence ” or the “ Company ”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that its joint venture functional mushroom brand GOODMIND™ has partnered with one of Africa’s largest coffee... Read More

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“ Psyence ” or the “ Company ”), a life science biotechnology company with a focus on natural psychedelics in mental health and well-being, announces that the Unaudited Condensed Consolidated Interim Financial Statements for the six months period ended September 30, 2021 and Management Discussion & Analysis (“MD&A”) for the three months ended September 30, 2021 will be filed on... Read More

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“ Psyence ” or the “ Company ”), a life science biotechnology company with a focus on natural psychedelics in mental health and well-being, will break new ground as the first psychedelic company invited to speak at the 15 th Annual Global Wellness Summit, a gathering of international leaders in the $4.5 trillion global wellness economy. 1 Meeting in Boston November 30 to... Read More